###AuthorName=MICHAEL KASSIOU
###AuthorTitle=PROFESSOR
###Affiliation=Faculty of Science
###Position=
##############################
LibraryCurrent studentsStaff Intranet
The University of Sydney
Faculty of Science
Refine search
Faculty of Science
Faculty of Science
University of Sydney
University of Sydney
All University websites
Library catalogue
Research opportunities
Staff directory
Courses
Researcher
Faculty of Science
University Home
Contacts
About Us
Faculty
People
Alumni
Important dates
Contact Us
You are here: University of Sydney / Faculty of Science / People / Our Staff / Academic Staff / Professor Michael Kassiou 
PEOPLE
Our Staff
expand
Academic Staff
Find an Academic
Research students
Science Hall of Fame
Women in Science
New staff
SEARCH PAGE
PROFESSOR MICHAEL KASSIOU
BSc PhD UNSW
Professor of Medicinal Chemistry
Interim Academic Director, Drug Discovery Initiative
F11 - Chemistry Building
The University of Sydney
Telephone 61 2 9351 2745
Fax 61 2 9351 3329
Email michael.kassiou@sydney.edu.au
Website Research Group Website
Contact Details
Map
Map data ©2017 Google
Terms of Use
Report a map error
Map
View in larger map
Biographical details
Michael received his PhD in Organic Chemistry in 1992 from the University of NSW. Following this he took up a position as research scientist within the Biomedicine and Health Program at the Australian Nuclear Science and Technology Organisation (ANSTO). In 1993 he was appointed as a visiting scientist at the CEA-Service Hospitalier Frédéric Joliot Life Sciences group in France looking at methods for studying the living brain. Shortly after that Michael took up a postdoctoral position at the Johns Hopkins Medical Institutes in Baltimore USA. In 1996 he was awarded a Fogerty Fellowship that saw him take up a position at the NIH National Institute of Drug Abuse (NIDA) USA. He then moved back to Sydney to the Department of PET and Nuclear Medicine at the Royal Prince Alfred Hospital as a Principal Hospital Scientist and in 2006 took up a position at the University of Sydney in which he is currently Professor of Medicinal Chemistry. He is also an Honorary Professor with the Centre for Advanced Imaging at The University of Queensland and elected in 2017 to the position of Director for the Society of Radiopharmaceutical Sciences. He is the Editor for the Journal of Labelled Compounds and Radiopharmaceuticals and Associate Editor for Frontiers in Experimental Pharmacology and Drug Discovery. He is an editorial advisory board member for ACS Chemical Neuroscience and ChemMedChem, in addition to 10 other journal editorial advisory boards concerned with medicinal chemistry and drug design.
Back to Top
Research interests
Medicinal Chemistry and Drug Discovery
Structure-activity relationships of CNS bioactive molecules
Rationale CNS drug design and evaluation
Heterocyclic Chemistry
Research in my group is interdisciplinary and built around the key themes of medicinal chemistry and drug discovery. Our research group utilises modern organic chemistry techniques to rationally design and synthesise novel compounds for a range of CNS targets which are associated with neuropathologie ssuch as Parkinson’s disease, schizophrenia, anxiety and depression. In this domain understanding drug-protein and drug-binding site interactions is a key component which allows us to obtain structure-activity relationships of bioactive CNS molecules. In addition by using molecular imaging techniques within these fields we are able to better understand the living brain in normal and diseased states through in vivo studies.
Back to Top
Current research students
Project title Research student
The design, synthesis and evaluation of novel CB2 ligands Annukka KALLINEN
The synthesis of novel non-peptide based small oxytocin receptor agonists Tim KATTE
The design and synthesis of novel selective cannabinoid receptor type 2 ligands Michael MOIR
Novel P2X7 Receptor Ligands James O'BRIEN-BROWN
Translocator Protein (TSPO) Ligands for Neurotherapeutic and Anticancer Purposes Renee SOKIAS
Back to Top
Current projects
For current research activities and opportunities please visit our home page: http://www.chem.usyd.edu.au/~kassiou
Back to Top
PhD and master's project opportunities
Drug Discovery and Medicinal Chemistry for the Central Nervous System
Back to Top
Selected grants
2018
Frontotemporal dementia and motor neurodegenerative syndromes; Halliday G, Halliday G, Mattick J, Hodges J, Hodges J, Kiernan M, Piguet O, Piquet O, Kril J, Ittner L, Ittner L, Kassiou M; National Health and Medical Research Council (NHMRC)/Program Grants.
2017
Ion Channel Drug Discovery Consortium; Collins M, MacDonald C, Kassiou M, Ahring J, Fuller S, Vandenberg R, Balle T, Ryan R, Imlach W; DVC Research/Sydney Research Excellence Initiative 2020 (SREI).
2016
P2X7 receptor-based microglia PET imaging in Parkinson's Disease; Kassiou M; Michael J Fox Foundation for Parkinsons Research/Research Support.
Dynamics of M1/M2 polarization of microglia in multiple sclerosis: a PET imaging study; de Vries H, Kassiou M; Merck Serono Australia Pty Ltd/Grant for Multiple Sclerosis Innovation (GMSI).
Probing Anaesthetic Effects with New Functional Imaging Paradigms; Kassiou M, Fulton R; Australian Research Council (ARC)/Discovery Projects (DP).
DYRK1A as a novel target for glioblastoma therapies; Kassiou M, Johns T, Munoz L; National Health and Medical Research Council (NHMRC)/Project Grants.
Understanding effects of synthetic cannabinoids on human health; Kassiou M, McGregor I, Connor M; National Health and Medical Research Council (NHMRC)/Project Grants.
2015
A Mouse Biotelemetry System for Stroke, Epilepsy and Sleep Research; McGregor I, Collins M, Grunstein R, Kassiou M, Bowen M; DVC Research/Equipment Grant.
Preparative High-Performance Liquid Chromatograph (Preparative-HPLC) for Expediting Drug Translation; Codd R, Payne R, Kassiou M, Groundwater P, Munoz L; DVC Research/Equipment Grant.
Targeting Post-synaptic Tau to Treat Alzheimers Disease; Kassiou M; National Health and Medical Research Council (NHMRC)/Project Grants.
Novel therapeutics for the remediation of social deficits in psychiatric illness; McGregor I, Kassiou M, Hunt G; National Health and Medical Research Council (NHMRC)/Project Grants.
2014
University of Sydney Automated Peptide Synthesis Platform; Payne R, Britton W, Byrne S, Chan K, Clarke R, Hunt N, Jolliffe K, Kassiou M, Lay P, Mackay J, Matthews J, McErlean C, New E, Rasmussen H, Rendina L, Rudrawar S, Rutledge P, Shepherd N; National Health and Medical Research Council (NHMRC)/Equipment Grants.
2013
Sydney Neuroscience Network; Balleine B, Absalom N, Braddon-Mitchell D, Callaghan S, Chawla S, Christie M, Collins M, Einfeld S, Grieve S, Haber P, Hanrahan J, Harris A, Hickie I, Kassiou M, Kril J, Meikle S, Morris R, Ramos F, Rong Y, Sue C; DVC Research/Research Network Scheme (SyReNS).
Development of small molecule inhibitors of LRRK2 for treatment of Parkinsons disease; Kassiou M, Munoz L; Parkinsons New South Wales Incorporated/Research Support.
Mouse behavioural phenotyping battery; Hunt N, Christie M, McGregor I, Kassiou M, Collins M, Stone J, Arnold J, Sawatari A, Mitrofanis J, Camp A; National Health and Medical Research Council (NHMRC)/Equipment Grants.
HPLC-MS for high throughput drug and protein analysis; Payne R, Kassiou M, Cordwell S, Hibbs D, Groundwater P, Shepherd N; DVC Research/Equipment Grant.
2012
A flexible high throughput analytical system for psychopharmacology and drug discovery; McGregor I, Simpson S, Weickert C, Kassiou M, Copeland J, Solowij N, Codd R, Arnold J, Karl T, Long L; Australian Research Council (ARC)/Linkage Infrastructure, Equipment and Facilities (LIEF).
Oxytocin receptor agonists for treatment of social anxiety; Kassiou M, McGregor I, Hunt G; National Health and Medical Research Council (NHMRC)/Project Grants.
A unique class of tumour-specific drugs for the trearment of advanced metastatic cancer; Rendina L, Kassiou M; National Breast Cancer Foundation/Novel Concept Awards.
New Strategies in the Treatment and Imaging of Neurodegenerative Diseases; Kassiou M; National Health and Medical Research Council (NHMRC)/International Collaborations: Australian-European Union Health Research Grants.
2011
Imaging of neuroinflammation in neurodegenerative disease (INMiND); Jacobs A, Maggi A, Aigner L, Guilloteau D, Aime S, Planas A, Van Der Linden A, Tavitian B, Herholz K, Boutin H, Perani D, Halldin C, Nordberg A, Van Laere K, Baekelandt V, Knudsen G, Pappata S, Rinne J, Holmes C, Roncaroli F, Brooks D, Kassiou M, Kellermayer M, Heneka M, Biserni A, Perk I, Cavallotti C, Alavijeh M, Mathe D, Ronn L; European Commission (Belgium)/Seventh Framework Network of Excellence Programme.
Molecular targets of amino acid/neurotransmitter conjugates of fatty acids; Connor M, Vaughan C, Kassiou M, McIntyre P; National Health and Medical Research Council (NHMRC)/Project Grants.
The Development of Carboranes as New Agents in the Diagnosis and Treatment of Brain Disease; Kassiou M, Rendina L; Australian Research Council (ARC)/Discovery Projects (DP).
Preclinical validation of oxytocin as a novel treatment for alcohol dependence; McGregor I, Hunt G, Kassiou M; National Health and Medical Research Council (NHMRC)/Project Grants.
Preparative High-Performance Liquid Chromatography (HPLC); Payne R, Jolliffe K, Hambley T, Kassiou M, Collins M; National Health and Medical Research Council (NHMRC)/Equipment Grants.
2010
Purinergic P2X7 Receptor as a Target for Antidepressant Drug Discovery; Kassiou M, McGregor I, Bennett M; National Health and Medical Research Council (NHMRC)/Project Grants.
Radiolabelled MMP Binding Agents for the Identification, Quantification, and Targeting of MMPs in CNS Disorders and Tumours; Hambley T, Kassiou M; Australian Research Council (ARC)/Discovery Projects (DP).
The translocator protein (TSPO) as a novel target for the treatment of Alzheimers Disease; Ittner L, Kassiou M; National Health and Medical Research Council (NHMRC)/Project Grants.
2009
Selective Targeting of Breast Tumours for Boron Neutron Capture Therapy; Rendina L, Kassiou M; National Breast Cancer Foundation/Novel Concept Awards.
Hidex Chameleon V Multi-Technology plate reader; Ittner L, Goetz J, MacDonald C, Kassiou M, Connor M, Holsinger D; National Health and Medical Research Council (NHMRC)/Equipment Grants.
Motion Menura multimodal mouse testing apparatus (MMTA): (Turnkey system comprising 6 testing chambers with associated control and tracking software).; Kemp A, Hermens D, McGregor I, Einfeld S, Kassiou M, Arnold J, Hunt G; National Health and Medical Research Council (NHMRC)/Equipment Grants.
2008
RES: Contract Research Agreement with Bayer Schering Pharma; Kassiou M; Bayer Schering Pharma AG/Research Support.
Development of Novel Radiolabelled Molecular Probes for Studying Diseases of the Brain; Kassiou M; Department of Industry, Innovation and Science/International Science Linkages (ISL) Competitive Grants.
Research Infrastructure (Major Equipment) Scheme 2008; Ittner L, Goetz J, Christie M, Bennett M, Kassiou M, Connor M, Holsinger D, Bagley E; Faculty of Medicine/Linkage Infrastructure, Equipment and Facilities (LIEF).
The Targeting of Brain Tumours by a New Class of Agents for Boron Neutron Capture Therapy; Rendina L, Kassiou M; Cure Cancer Australia Foundation/Research Support.
2007
Automatic Gamma Counter; Meikle S, Banati R, Kassiou M, Bailey D, Baldock C; National Health and Medical Research Council (NHMRC)/Equipment Grants.
Establishment of a National Imaging Facility; Banati R, Meikle S, Kassiou M; Department of Education, Science and Training (DEST)/National Collaborative Research Infrastructure Strategy (Australia).
National Imaging Facility; Meikle S, Kassiou M, Banati R; Office for Science and Medical Research (NSW)/National Collaborative Research Infrastructure Strategy Program.
Evaluation of a selective NMDA NR1A/2B receptor antagonist as a drug treatment in an animal model of Parkinsons disease; Henderson J, Kassiou M; Australian Rotary Health/Research Grant.
Development of Novel Radiolabelled Molecular Probes for Studying Diseases of the Brain; Meikle S, Banati R, Kassiou M; DEST/International Science Linkages Competitive Grants.
2006
Functionalised MMP Inhibitors as Radiodiagnostic, Radiotherapeutic, and Radiation-Sensitising Agents for Metastatic Cancer; Hambley T, Kassiou M; Australian Research Council (ARC)/Discovery Projects (DP).
2005
Evaluation of a selective NMDA NR1A/2B receptor antagonist as a drug treatment in an animal model of Parkinsons disease.; Henderson J, Kassiou M; Australian Rotary Health/Parkinsons Disease.
Glial and neuroinflammatory mechanisms of neuronal degeneration and regeneration: The functional states of microglia in central nervous system and macrophages in the peripheral nervous system.; Pollard J, Kassiou M, Prineas J, Banati R, Bennett M; NSW Ministry of Science and Medical Research/Spinal Cord Injury Research Grants.
2004
Functional in vivo imaging of neurodegenerative disorders of the brain using PET & SPECT; Kassiou M, Guilloteau D; DEST/Innovation Access Program.
Development and evaluation of a SPECT radioligand for imaging the sigma receptor; Kassiou M; Australian Institute of Nuclear Science and Engineering (AINSE)/Awards.
1295 - Comparison of structurally diverse SPECT radioligands for the peripheral benzodiazepine receptor; Kassiou M; Australian Institute of Nuclear Science and Engineering (AINSE)/Awards.
2003
Trishomocubanes: Potential neuroprotective drug therapies for Parkinsons disease; Henderson J, Kassiou M; Brain Foundation of Australia/Research Grants.
Development of radioligands for imaging the NMDA receptor using Positron Emission Tomography (PET); Kassiou M; Embassy of France in Australia/Research Grant.
2002
Not known; Kassiou M; DVC Research/Research and Development Scheme: Research and Development (R&D).
Show more
Back to Top
Selected publications
Download citations: PDF RTF Endnote
By type
By year
Expand all
Book Chapters
Barron, M., Werry, E., McGregor, I., Kassiou, M. (2014). P2X7 in Bipolar and Depressive Disorders. In Norbert Weiss, Alexandra Koschak (Eds.), Pathologies of Calcium Channels, (pp. 635-661). Berlin: Springer-Verlag.
Guenther, K., Hambley, T., Kassiou, M. (2008). Radiolabelled probes for imaging multidrug resistance using single photon emission tomography (SPECT) and positron emission tomography (PET). In Nicola Antonio Colabufo (Eds.), Multidrug Resistance: Biological and Pharmaceutical Advances in Antitumour Treatment, (pp. 291-320). India: Research Signpost.
Journals
Kevin, R., Wood, K., Stuart, J., Mitchell, A., Moir, M., Banister, S., Kassiou, M., McGregor, I. (2017). Acute and residual effects in adolescent rats resulting rrom exposure to the novel synthetic cannabinoids AB-PINACA and AB-FUBINACA. Journal of Psychopharmacology, 31(6), 757-769. [More Information]
Sridharan, S., Lepelletier, F., Trigg, W., Banister, S., Reekie, T., Kassiou, M., Gerhard, A., Hinz, R., Boutin, H. (2017). Comparative evaluation of three TSPO PET radiotracers in a LPS-induced model of mild neuroinflammation in rats. Molecular Imaging and Biology, 19(1), 77-89. [More Information]
Werry, E., King, V., Barron, M., Banister, S., Sokias, R., Kassiou, M. (2017). Derivatives of the pyrazolo[1,5-a]pyrimidine acetamide DPA-713 as translocator protein (TSPO) ligands and pro-apoptotic agents in human glioblastoma. European Journal of Pharmaceutical Sciences, 96, 186-192. [More Information]
Sokias, R., Werry, E., Chua, S., Reekie, T., Munoz, L., Ittner, L., Kassiou, M. (2017). Determination and reduction of translocator protein (TSPO) ligand rs6971 discrimination. MedChemComm (Medicinal Chemistry Communications), 8(1), 202-210. [More Information]
O'Brien-Brown, J., Jackson, A., Reekie, T., Barron, M., Werry, E., Schiavini, P., McDonnell, M., Munoz, L., Wilkinson, S., Noll, B., Kassiou, M., et al (2017). Discovery and pharmacological evaluation of a novel series of adamantyl cyanoguanidines as P2X7 receptor antagonists. European Journal of Medicinal Chemistry, 130, 433-439. [More Information]
Coughlin, J., Wang, Y., Minn, I., Bienko, N., Ambinder, E., Kassiou, M., Xu, X., et al (2017). Imaging of glial cell activation and white matter integrity in brains of active and recently retired national football league players. JAMA Neurology, 74(1), 67-74. [More Information]
Katte, T., Reekie, T., Werry, E., Jorgensen, W., Boyd, R., Wong, E., Gulliver, D., Connor, M., Kassiou, M. (2017). Investigation of pyrazolo-sulfonamides as putative small molecule oxytocin receptor agonists. European Journal of Medicinal Chemistry, 136, 330-333. [More Information]
Gunosewoyo, H., Yu, L., Munoz, L., Kassiou, M. (2017). Kinase targets in CNS drug discovery. Future Medicinal Chemistry, 9(3), 303-314. [More Information]
Ahmed, R., Irish, M., van Eersel, J., Ittner, A., Ke, Y., Volkerling, A., van der Hoven, J., Tanaka, K., Karl, T., Kassiou, M., Kril, J., Piguet, O., Kiernan, M., Halliday, G., Hodges, J., et al (2017). Mouse models of frontotemporal dementia: A comparison of phenotypes with clinical symptomatology. Neuroscience and Biobehavioral Reviews, 74(1 March 2017), 126-138. [More Information]
Wang, Y., Coughlin, J., Ma, S., Endres, C., Kassiou, M., Sawa, A., Dannals, R., Petri, M., Pomper, M. (2017). Neuroimaging of translocator protein in patients with systemic lupus erythematosus: a pilot study using [11C]DPA-713 positron emission tomography. Lupus, 26(2), 170-178. [More Information]
Wong, E., Reekie, T., Werry, E., O'Brien-Brown, J., Bowyer, S., Kassiou, M. (2017). Pharmacological evaluation of a novel series of urea, thiourea and guanidine derivatives as P2X(7) receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 27(11), 2439-2442. [More Information]
Reekie, T., Wilkinson, S., Law, V., Hibbs, D., Ong, J., Kassiou, M. (2017). Rapid access to N-(indol-2-yl)amides and N-(indol-3-yl)amides as unexplored pharmacophores. Organic and Biomolecular Chemistry, 15(3), 576-580. [More Information]
Zhou, Q., Phoa, A., Abbassi, R., Hoque, M., Reekie, T., Font Sadurni, J., Ryan, R., Stringer, B., Day, B., Johns, T., Munoz, L., Kassiou, M. (2017). Structural optimization and pharmacological evaluation of inhibitors targeting dual-specificity tyrosine phosphorylation-regulated kinases (DYRK) and CDC-like kinases (CLK) inglioblastoma. Journal of Medicinal Chemistry, 60(5), 2052-2070. [More Information]
Chua, S., Cornejo, A., van Eersel, J., Stevens, C., Vaca, I., Cueto, M., Kassiou, M., Gladbach, A., Macmillan, A., Lewis, L., et al (2017). The polyphenol altenusin inhibits in vitro fibrillization of tau and reduces induced tau pathology in primary neurons. ACS Chemical Neuroscience, 8(4), 743-751. [More Information]
Conroy, T., Manohar, M., Gong, Y., Wilkinson, S., Webster, M., Lieberman, B., Banister, S., Reekie, T., Mach, R., Rendina, L., Kassiou, M. (2016). A systematic exploration of the effects of flexibility and basicity on sigma (sigma) receptor binding in a series of substituted diamines. Organic and Biomolecular Chemistry, 14(39), 9388-9405. [More Information]
Thomas, C., Vercouillie, J., Domene, A., Tauber, C., Kassiou, M., Guilloteau, D., Destrieux, C., Serriere, S., Chalon, S. (2016). Detection of neuroinflammation in a rat model of subarachnoid hemorrhage using [18F]DPA-714 PET imaging. Molecular Imaging, 15, 1-8. [More Information]
Przybyla, M., Stevens, C., Hoven, J., Harasta, A., Bi, M., Ittner, A., Hummel, A., Hodges, J., Piguet, O., Karl, T., Kassiou, M., et al (2016). Disinhibition-like behavior in a P301S mutant tau transgenic mouse model of frontotemporal dementia. Neuroscience Letters, 631, 24-29. [More Information]
Jorgensen, W., Gulliver, D., Werry, E., Reekie, T., Connor, M., Kassiou, M. (2016). Flexible analogues of WAY-267,464: Synthesis and pharmacology at the human oxytocin and vasopressin 1a receptors. European Journal of Medicinal Chemistry, 108, 730-740. [More Information]
Coughlin, J., Wang, Y., Ambinder, E., Ward, R., Minn, I., Vranesic, M., Kim, P., Ford, C., Higgs, C., Hayes, L., Kassiou, M., et al (2016). In vivo markers of inflammatory response in recent-onset schizophrenia: a combined study using [11C]DPA-713 PET and analysis of CSF and plasma. Translational Psychiatry, 6(4), 1-8. [More Information]
Ramos, L., Hicks, C., Caminer, A., Couto, K., Narlawar, R., Kassiou, M., McGregor, I. (2016). MDMA ('Ecstasy'), oxytocin and vasopressin modulate social preference in rats: A role for handling and oxytocin receptors. Pharmacology, Biochemistry and Behavior, 150-151, 115-123. [More Information]
Banister, S., Longworth, M., Kevin, R., Sachdev, S., Santiago, M., Stuart, J., Mack, J., Glass, M., McGregor, I., Connor, M., Kassiou, M. (2016). Pharmacology of Valinate and tert-Leucinate Synthetic Cannabinoids 5F-AMBICA, 5F-AMB, 5F-ADB, AMB-FUBINACA, MDMB-FUBINACA, MDMB-CHMICA, and Their Analogues. ACS Chemical Neuroscience, 7(9), 1241-1254. [More Information]
Dupont, A., Guilloteau, D., Kassiou, M., Ribeiro, M., Vercouillie, J., Katsifis, A., Arlicot, N. (2016). Radiopharmaceuticals for PET imaging of neuroinflammation. Medecine Nucleaire, 40(1), 72-81. [More Information]
Kandemir, H., Sengul, I., Gardner, C., Werry, E., Barron, M., Kassiou, M., Kumar, N., Black, D. (2016). Synthesis of 7,7'-linked-bis-indoles via 7-tryptamines. Heterocycles, 93(1), 333-346. [More Information]
Longworth, M., Banister, S., Mack, J., Glass, M., Connor, M., Kassiou, M. (2016). The 2-alkyl-2H-indazole regioisomers of synthetic cannabinoids AB-CHMINACA, AB-FUBINACA, AB-PINACA, and 5F-AB-PINACA are possible manufacturing impurities with cannabimimetic activities. Forensic Toxicology, 34(2), 286-303. [More Information]
Katte, T., Reekie, T., Jorgensen, W., Kassiou, M. (2016). The Formation of Seven-Membered Heterocycles under Mild Pictet-Spengler Conditions: A Route to Pyrazolo[3,4]benzodiazepines. The Journal of Organic Chemistry, 81(11), 4883-4889. [More Information]
Beinat, C., Banister, S., Herrera, M., Kassiou, M. (2016). The recent development of ?7 nicotinic acetylcholine receptor (nAChR) ligands as therapeutic candidates for the treatment of central nervous system (CNS) diseases. Current Pharmaceutical Design, 22(14), 2134-2151. [More Information]
Serriere, S., Tauber, C., Vercouillie, J., Mothes, C., Pruckner, C., Guilloteau, D., Kassiou, M., Domene, A., Garreau, L., Page, G., et al (2015). Amyloid load and translocator protein 18 kDa in APPswePS1-dE9 mice: a longitudinal study. Neurobiology of Aging, 36(4), 1639-1652. [More Information]
Wilkinson, S., Banister, S., Kassiou, M. (2015). Bioisosteric fluorine in the clandestine design of synthetic cannabinoids. Australian Journal of Chemistry, 68(1), 4-8. [More Information]
Austin, C., Moir, M., Kahlert, J., Smith, J., Jamie, J., Kassiou, M., Rendina, L. (2015). Carborane-containing hydroxyamidine scaffolds as novel inhibitors of indoleamine 2,3-dioxygenase 1 (IDO1). Australian Journal of Chemistry, 68(12), 1866-1870. [More Information]
Abbassi, R., Johns, T., Kassiou, M., Munoz, L. (2015). DYRK1A in neurodegeneration and cancer: Molecular basis and clinical implications. Pharmacology & Therapeutics, 151, 87-98. [More Information]
Banister, S., Stuart, J., Kevin, R., Edington, A., Longworth, M., Wilkinson, S., Beinat, C., Buchanan, A., Hibbs, D., Glass, M., McGregor, I., Kassiou, M., et al (2015). Effects of Bioisosteric Fluorine in Synthetic Cannabinoid Designer Drugs JWH-018, AM-2201, UR-144, XLR-11, PB-22, 5F-PB-22, APICA, and STS-135. ACS Chemical Neuroscience, 6(8), 1445-1458. [More Information]
Banister, S., Beinat, C., Wilkinson, S., Shen, B., Bartoli, C., Selleri, S., Da Pozzo, E., Martini, C., Chin, F., Kassiou, M. (2015). Ether analogues of DPA-714 with subnanomolar affinity for the translocator protein (TSPO). European Journal of Medicinal Chemistry, 93, 392-400. [More Information]
Santiago-Ribeiro, M., Vercouillie, J., Cottier, J., Debiais, S., Bonnaud, I., Annan, M., Maia, S., Kassiou, M., Arlicot, N., Guilloteau, D. (2015). Evaluation en TEP de l'activation microgliale apres un accident vasculaire cerebral. Medecine Nucleaire, 39(3), 210-210. [More Information]
Narlawar, R., Werry, E., Scarf, A., Hanani, R., Chua, S., King, V., Barron, M., Martins, R., Ittner, L., Rendina, L., Kassiou, M. (2015). First demonstration of positive allosteric-like modulation at the human wild type translocator protein (TSPO). Journal of Medicinal Chemistry, 58(21), 8743-8749. [More Information]
Lee, D., Yue, X., Ibrahim, W., Lentz, M., Peterson, K., Jagoda, E., Kassiou, M., Maric, D., Reid, W., Hammoud, D. (2015). Lack of neuroinflammation in the HIV-1 transgenic rat: an [18F]-DPA714 PET imaging study. Journal of Neuroinflammation, 12(171), 1-11. [More Information]
Coughlin, J., Wang, Y., Munro, C., Ma, S., Yue, C., Chen, S., Airan, R., Kim, P., Adams, A., Garcia, C., Kassiou, M., et al (2015). Neuroinflammation and brain atrophy in former NFL players: An in vivo multimodal imaging pilot study. Neurobiology of Disease, 74, 58-65. [More Information]
Munoz, L., Kavanagh, M., Phoa, A., Heng, B., Dzamko, N., Chen, E., Doddareddy, M., Guillemin, G., Kassiou, M. (2015). Optimisation of LRRK2 inhibitors and assessment of functional efficacy in cell-based models of neuroinflammation. European Journal of Medicinal Chemistry, 95, 29-34. [More Information]
Banister, S., Moir, M., Stuart, J., Kevin, R., Wood, K., Longworth, M., Wilkinson, S., Beinat, C., Buchanan, A., Glass, M., McGregor, I., Kassiou, M., et al (2015). Pharmacology of indole and indazole synthetic cannabinoid designer drugs AB-FUBINACA, ADB-FUBINACA, AB-PINACA, ADB-PINACA, 5F-AB-PINACA, 5F-ADB-PINACA, ADBICA, and 5F-ADBICA. ACS Chemical Neuroscience, 6(9), 1546-1559. [More Information]
Phoa, A., Brown, S., Gurgis, F., Akerfeldt, M., Döbber, A., Renn, C., Peifer, C., Stringer, B., Day, B., Wong, C., Chircop (nee Fabbro), M., Kassiou, M., Munoz, L., et al (2015). Pharmacology of novel small-molecule tubulin inhibitors in glioblastoma cells with enhanced EGFR signalling. Biochemical Pharmacology, 98(4), 587-601. [More Information]
Manohar, M., Banister, S., Beinat, C., O'Brien-Brown, J., Kassiou, M. (2015). Recent advances in the development of sigma-1 receptor ligands. Australian Journal of Chemistry, 68, 600-609. [More Information]
Beinat, C., Reekie, T., Banister, S., O'Brien-Brown, J., Xie, T., Olson, T., Xiao, Y., Harvey, A., O'Connor, S., Coles, C., Kassiou, M., et al (2015). Structure-activity relationship studies of SEN12333 analogues: Determination of the optimal requirements for binding affinities at alpha7 nAChRs through incorporation of known structural motifs. European Journal of Medicinal Chemistry, 95, 277-301. [More Information]
Banister, S., Stuart, J., Conroy, T., Longworth, M., Manohar, M., Beinat, C., Wilkinson, S., Kevin, R., Hibbs, D., Glass, M., McGregor, I., Kassiou, M., et al (2015). Structure-activity relationships of synthetic cannabinoid designer drug RCS-4 and its regioisomers and C4 homologues. Forensic Toxicology, 33(2), 355-366. [More Information]
Beinat, C., Banister, S., Herrera, M., Law, V., Kassiou, M. (2015). The therapeutic potential of alpha7 nicotinic acetylcholine receptor (apha7 nAChR) agonists for the treatment of the cognitive deficits associated with schizophrenia. CNS Drugs, 29(7), 529-542. [More Information]
Werry, E., Barron, M., Kassiou, M. (2015). TSPO as a target for glioblastoma therapeutics. Biochemical Society Transactions, 43, 531-536. [More Information]
Hicks, C., Ramos, L., Reekie, T., Narlawar, R., Kassiou, M., McGregor, I. (2015). WAY 267,464, a non-peptide oxytocin receptor agonist, impairs social recognition memory in rats through a vasopressin 1A receptor antagonist action. Psychopharmacology, 232, 2659-2667. [More Information]
Medran-Navarrete, V., Bernards, N., Kuhnast, B., Damont, A., Pottier, G., Peyronneau, M., Kassiou, M., Marguet, F., Puech, F., Boisgard, R., et al (2014). [18F]DPA-C5yne, a novel fluorine-18-labelled analogue of DPA-714: radiosynthesis and preliminary evaluation as a radiotracer for imaging neuroinflammation with PET. Journal of Labelled Compounds and Radiopharmaceuticals, 57(6), 410-418. [More Information]
Liang, V., Ullrich, M., Lam, H., Chew, Y., Banister, S., Song, X., Zaw, T., Kassiou, M., Goetz, J., Nicholas, H. (2014). Altered proteostasis in aging and heat shock response in C. elegans revealed by analysis of the global and de novo synthesized proteome. Cellular and Molecular Life Sciences, 71(17), 3339-3361. [More Information]
Ullrich, M., Liang, V., Chew, Y., Banister, S., Song, X., Zaw, T., Lam, H., Berber, S., Kassiou, M., Nicholas, H., Goetz, J. (2014). Bio-orthogonal labeling as a tool to visualize and identify newly synthesized proteins in Caenorhabditis elegans. Nature Protocols, 9(9), 2237-2255. [More Information]
Hicks, C., Ramos, L., Reekie, T., Misagh, G., Narlawar, R., Kassiou, M., McGregor, I. (2014). Body temperature and cardiac changes induced by peripherally administered oxytocin, vaspressin and the non-peptide oxytocin receptor agonist WAY 267, 464: a biotelemetry study in rats. British Journal of Pharmacology, 171(11), 2868-2887. [More Information]
Ribeiro, M., Vercouillie, J., Debiais, S., Cottier, J., Bonnaud, I., Camus, V., Banister, S., Kassiou, M., Arlicot, N., Guilloteau, D. (2014). Could 18F DPA 714 PET imaging be interesting to use in the early post-stroke period? European Journal of Nuclear Medicine and Molecular Imaging, 4(28), 1-8. [More Information]
Zavitsanou, K., Lim, C., Purves-Tyson, T., Karl, T., Kassiou, M., Banister, S., Guillemin, G., Weickert, C. (2014). Effect of maternal immune activation on the kynurenine pathway in preadolescent rat offspring and on MK801-induced hyperlocomotion in adulthood: Amelioration by COX2 inhibition. Brain, Behavior, and Immunity, 41, 173-181. [More Information]
Beinat, C., Reekie, T., Hibbs, D., Xie, T., Olson, T., Xiao, Y., Harvey, A., O'Connor, S., Coles, C., Tsanaktsidis, J., Kassiou, M. (2014). Investigations of amide bond variation and biaryl modification in analogues of alpha7 nAChR agonist SEN12333. European Journal of Medicinal Chemistry, 84, 200-205. [More Information]
Gent, Y., Weijers, K., Molthoff, C., Windhorst, A., Huisman, M., Kassiou, M., Jansen, G., Lammertsma, A., van der Laken, C. (2014). Promising potential of new generation translocator protein tracers providing enhanced contrast of arthritis imaging by positron emission tomography in a rat model of arthritis. Arthritis Research & Therapy, 16(2), 1-9. [More Information]
Reekie, T., McGregor, I., Kassiou, M. (2014). Pyrazolo 1,4 diazepines as non-peptidic probes of the oxytocin and vasopressin receptors. Tetrahedron Letters, 55(33), 4568-4571. [More Information]
Coughlin, J., Wang, Y., Ma, S., Yue, C., Kim, P., Adams, A., Roosa, H., Gage, K., Stathis, M., Rais, R., Kassiou, M., et al (2014). Regional brain distribution of translocator protein using 11C DPA-713 PET in individuals infected with HIV. Journal of neurovirology, 20(3), 219-232. [More Information]
Beinat, C., Banister, S., Hoban, J., Tsanaktsidis, J., Metaxas, A., Windhorst, A., Kassiou, M. (2014). Structure-activity relationships of N-substituted 4-(trifluoromethoxyl)benzamidines with affinity for GluN2B-containing NMDA receptors. Bioorganic & Medicinal Chemistry Letters, 24(3), 828-830. [More Information]
Wilkinson, S., Gunosewoyo, H., Barron, M., Boucher, A., McDonnell, M., Turner, P., Morrison, D., Bennett, M., McGregor, I., Rendina, L., Kassiou, M. (2014). The first CNS-active carborane: A novel P2X7 receptor antagonist with antidepressant activity. ACS Chemical Neuroscience, 5(5), 335-339. [More Information]
Chua, S., Kassiou, M., Ittner, L. (2014). The translocator protein as a drug target in Alzheimer's disease. Expert Review of Neurotherapeutics, 14(4), 439-448. [More Information]
Boutin, H., Prenant, C., Maroy, R., Galea, J., Greenhalgh, A., Smigova, A., Cawthorne, C., Julyan, P., Wilkinson, S., Banister, S., Kassiou, M., et al (2013). [(18)F]DPA-714: Direct comparison with [(11)C]PK11195 in a model of cerebral ischemia in rats. PloS One, 8673 (2), 1-9. [More Information]
Beinat, C., Banister, S., McErlean, C., Kassiou, M. (2013). A practical synthesis of (1S,4S)-2,5-diazabicyclo[2.2.1]heptane. Tetrahedron Letters, 54(39), 5345-5347. [More Information]
Ramos, L., Hicks, C., Kevin, R., Caminer, A., Narlawar, R., Kassiou, M., McGregor, I. (2013). Acute Prosocial Effects of Oxytocin and Vasopressin When Given Alone or in Combination with 3,4-Methylenedioxymethamphetamine in Rats: Involvement of the VI(A) Receptor. Neuropsychopharmacology, 38(11), 2249-2259. [More Information]
Ribeiro, M., Vercouillie, J., Corcia, P., Arlicot, N., Erra, B., Maia, S., Bonnaud, I., Debiais, S., Kassiou, M., Guilloteau, D. (2013). Cerebral biodistribution of the PET TSPO radioligand, (18)F-DPA-714, in acute and chronic brain diseases. Journal of Labelled Compounds and Radiopharmaceuticals, 56(S1), P219-P219.
Wilkinson, S., Price, J., Kassiou, M. (2013). Improved accessibility to the desoxy analogues of delta(9)-tetrahydrocannabinol and cannabidiol. Tetrahedron Letters, 54(1), 52-54. [More Information]
Schollhorn-Peyronneau, M., Saba, W., Goutal, S., Damont, A., Dolle, F., Kassiou, M., Bottlaender, M., Valette, H. (2013). Metabolism and quantification of [(18)F]DPA-714, a new TSPO positron emission tomography radioligand. Drug Metabolism and Disposition, 41(1), 122-131. [More Information]
Santiago-Ribeiro, M., Vercouillie, J., Cottier, J., Debiais, S., Bonnaud, I., Arlicot, N., Erra, B., Maia, S., Kassiou, M., Guilloteau, D. (2013). Microglia activation after acute stroke demonstrated using 18F-DPA-714 PET. Correlation with MRI. European Journal of Nuclear Medicine and Molecular Imaging, 40(S2), S208-S208. [More Information]
Banister, S., Manoli, M., Barron, M., Werry, E., Kassiou, M. (2013). N-substituted 8-aminopentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]undecanes as sigma receptor ligands with potential neuroprotective effects. Bioorganic and Medicinal Chemistry, 21(19), 6038-6052. [More Information]
Reekie, T., Kavanagh, M., Longworth, M., Kassiou, M. (2013). Synthesis of Biologically Active Seven-Membered-Ring Heterocycles. Synthesis: journal of synthetic organic chemistry, 45(23), 3211-3227. [More Information]
Kavanagh, M., Doddareddy, M., Kassiou, M. (2013). The development of CNS-active LRRK2 inhibitors using property-directed optimisation. Bioorganic & Medicinal Chemistry Letters, 23(13), 3690-3696. [More Information]
Banister, S., Manoli, M., Kassiou, M. (2013). The development of radiotracers for imaging sigma receptors in the central nervous system (CNS) using positron emission tomography (PET). Journal of Labelled Compounds and Radiopharmaceuticals, 56(3-4), 215-224. [More Information]
Kahlert, J., Austin, C., Kassiou, M., Rendina, L. (2013). The fifth element in drug design: Boron in medicinal chemistry. Australian Journal of Chemistry, 66(10), 1118-1123. [More Information]
Banister, S., Wilkinson, S., Longworth, M., Stuart, J., Apetz, N., English, K., Brooker, L., Goebel, C., Hibbs, D., Glass, M., McGregor, I., Kassiou, M., et al (2013). The Synthesis and Pharmacological Evaluation of Adamantane-Derived Indoles: Cannabimimetic Drugs of Abuse. ACS Chemical Neuroscience, 4(7), 1081-1092. [More Information]
Austin, C., Kahlert, J., Kassiou, M., Rendina, L. (2013). The translocator protein (TSPO): A novel target for cancer chemotherapy. The International Journal of Biochemistry and Cell Biology, 45(7), 1212-1216. [More Information]
Banister, S., Rendina, L., Kassiou, M. (2012). 7-azabicyclo[2.2.1]heptane as a scaffold for the development of selective sigma-2 (sigma-2) receptor ligands. Bioorganic and Medicinal Chemistry Letters, 22(12), 4059-4063. [More Information]
Banister, S., Wilkinson, S., Hanani, R., Reynolds, A., Hibbs, D., Kassiou, M. (2012). A practical, multigram synthesis of the 2-(2-(4-alkoxyphenyl)-5,7-dimethylpy-razolo[1,5-a]pyrimidin-3-yl)acetamide (DPA) class of high affinity translocator protein (TSPO) ligands. Tetrahedron Letters, 53(29), 3780-3783. [More Information]
Banister, S., Manoli, M., Doddareddy, M., Hibbs, D., Kassiou, M. (2012). A σ1 receptor pharmacophore derived from a series of N-substituted 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecan-3-ols (AHDS). Bioorganic & Medicinal Chemistry Letters, 22(19), 6053-6058. [More Information]
Beinat, C., Banister, S., Prehn, S., Doddareddy, M., Hibbs, D., Sako, M., Chebib, M., Tran, T., Al-Muhtasib, N., Xiao, Y., Kassiou, M. (2012). Consequences of linker length alteration of the alpha7 nicotinic acetylcholine receptor (nAChR) agonist, SEN12333. Bioorganic and Medicinal Chemistry Letters, 22(7), 2380-2384. [More Information]
Leaver, K., Reynolds, A., Bodard, S., Guilloteau, D., Chalon, S., Kassiou, M. (2012). Effects of Translocator Protein (18 kDa) Ligands on Microglial Activation and Neuronal Death in the Quinolinic-Acid-Injected Rat Striatum. ACS Chemical Neuroscience, 3(2), 114-119. [More Information]
Scarf, A., Luus, C., Da Pozzo, E., Selleri, S., Guarino, C., Martini, C., Ittner, L., Kassiou, M. (2012). Evidence for complex binding profiles and species differences at the translocator protein (TSPO) (18 kDa). Current Molecular Medicine, 12(4), 488-493. [More Information]
Moussa, I., Banister, S., Manoli, M., Doddareddy, M., Cui, J., Mach, R., Kassiou, M. (2012). Exploration of ring size in a series of cyclic vicinal diamines with sigma(1) receptor-affinity. Bioorganic & Medicinal Chemistry Letters, 22(17), 5493-5497. [More Information]
Gilmore, A., Heblinski, M., Reynolds, A., Kassiou, M., Connor, M. (2012). Inhibition of human recombinant T-type calcium channels by N-arachidonoyl 5-HT. British Journal of Pharmacology, 167(5), 1076-1088. [More Information]
Arlicot, N., Vercouillie, J., Ribeiro, M., Tauber, C., Venel, Y., Baulieu, J., Maia, S., Corcia, P., Stabin, M., Reynolds, A., Kassiou, M., et al (2012). Initial evaluation in healthy humans of [18F]DPA-714, a potential PET biomarker for neuroinflammation. Nuclear Medicine and Biology, 39(4), 570-578. [More Information]
Scarf, A., Aumann, K., Kassiou, M. (2012). Is there any correlation between binding and functional effects at the translocator protein (TSPO) (18 kDa)? Current Molecular Medicine, 12(4), 387-397. [More Information]
Corcia, P., Tauber, C., Vercoullie, J., Arlicot, N., Prunier, C., Praline, J., Nicolas, G., Venel, Y., Hommet, C., Baulieu, J., Kassiou, M., et al (2012). Molecular imaging of microglial activation in amyotrophic lateral sclerosis. PloS One, 7(12), 1-7. [More Information]
Endres, C., Coughlin, J., Gage, K., Watkins, C., Kassiou, M., Pomper, M. (2012). Radiation dosimetry and biodistribution of the TSPO ligand (11)C-DPA-713 in humans. The Journal of Nuclear Medicine, 53(2), 330-335. [More Information]
Gosling, J., Baker, S., Haynes, J., Kassiou, M., Pouton, C., Warfe, L., White, P., Scammells, P. (2012). Synthesis and Biological Evaluation of Adenosines with Heterobicyclic and Polycyclic N6-Substituents as Adenosine A1 Receptor Agonists. ChemMedChem: chemistry enabling drug discovery, 7(7), 1191-1201. [More Information]
Hicks, C., Jorgensen, W., Brown, C., Fardell, J., Koehbach, J., Gruber, C., Kassiou, M., Hunt, G., McGregor, I. (2012). The Nonpeptide Oxytocin Receptor Agonist WAY 267,464: Receptor-Binding Profile, Prosocial Effects and Distribution of c-Fos Expression in Adolescent Rats. Journal of Neuroendocrinology, 24(7), 1012-1029. [More Information]
Banister, S., Kassiou, M. (2012). The Therapeutic Potential of Sigma (sigma) Receptors for the Treatment of Central Nervous System Diseases: Evaluation of the Evidence. Current Pharmaceutical Design, 18(7), 884-901. [More Information]
Dolle, F., Kuhnast, B., Damont, A., van Camp, N., Kassiou, M., Tavitian, B., Boisgard, R. (2011). [18F]DPA-716 as a candidate for imaging the TSPO 18 kDa with PET: Radiosynthesis and comparative evaluation ([11C]DPA-713/[18F]DPA-714) in a rat model of neuroinflammation. Journal of Labelled Compounds and Radiopharmaceuticals, 54(1), S275-S275.
Vercouillie, J., Ribeiro, M., Tauber, C., Venel, Y., Baulieu, J., Maia, S., Reynolds, A., Kassiou, M., Guilloteau, D., Corcia, P. (2011). Biodistribution of the TSPO radioligand (18)F-DPA-714 in healthy volunteers. Journal of Labelled Compounds and Radiopharmaceuticals, 54(1), S255-S255.
Issa, F., Kassiou, M., Rendina, L. (2011). Boron in drug discovery: Carboranes as unique pharmacophores in biologically active compounds. Chemical Reviews, 111(9), 5701-5722. [More Information]
Drake, C., Boutin, H., Jones, M., Denes, A., McColl, B., Selvarajah, J., Hulme, S., Georgiou, R., Hinz, R., Gerhard, A., Kassiou, M., et al (2011). Brain inflammation is induced by co-morbidities and risk factors for stroke. Brain, Behavior, and Immunity, 25(6), 1113-1122. [More Information]
Dolle, F., Le Helleix, S., Schollhorn-Peyronneau, M., Saba, W., Banister, S., Tournier, N., Valette, H., Kassiou, M. (2011). Carbon-11-labelling of a novel, trishomocubane-derived, high affinity and selectivity DAT ligand. Journal of Labelled Compounds and Radiopharmaceuticals, 54(1), S276-S276.
Moussa, I., Banister, S., Akladios, F., Chua, S., Kassiou, M. (2011). Effects of linker elongation in a series of N-(2-benzofuranylmethyl)-N'-(methoxyphenylalkyl)piperazine sigma(1) receptor ligands. Bioorganic and Medicinal Chemistry Letters, 21(19), 5707-5710. [More Information]
Banister, S., Moussa, I., Jorgensen, W., Chua, S., Kassiou, M. (2011). Molecular hybridization of 4-azahexacyclo[5.4.1.0(2,6).0(3,10).0(5,9).0(8,11)]dodecane-3-ol with sigma (σ) receptor ligands modulates off-target activity and subtype selectivity. Bioorganic and Medicinal Chemistry Letters, 21(12), 3622-3626. [More Information]
Banister, S., Yoo, D., Chua, S., Cui, J., Mach, R., Kassiou, M. (2011). N-arylalkyl-2-azaadamantanes as cage-expanded polycarbocyclic sigma (sigma) receptor ligands. Bioorganic and Medicinal Chemistry Letters, 21(18), 5289-5292. [More Information]
Ribeiro, M., Vercouillie, J., Tauber, C., Venel, Y., Baulieu, J., Maia, S., Reynolds, A., Kassiou, M., Guilloteau, D., Corcia, P. (2011). P-167 The potential interest of the PET radioligand (18)F-DPA-714 in neuroinflammation. Journal of Labelled Compounds and Radiopharmaceuticals, 54(1), S256-S256.
Martin, A., Boisgard, R., Kassiou, M., Dolle, F., Tavitian, B. (2011). Reduced PBR/TSPO Expression After Minocycline Treatment in a Rat Model of Focal Cerebral Ischemia: A PET Study Using [(18)F]DPA-714. Molecular Imaging and Biology, 13(1), 10-15. [More Information]
Boucher, A., Arnold, J., Hunt, G., Spiro, A., Spencer, J., Brown, C., McGregor, I., Bennett, M., Kassiou, M. (2011). Resilience and Reduced C-FOS Expression in P2X7 Receptor Knockout Mice Exposed to Repeated Forced Swim Test. Neuroscience, 189, 170-177. [More Information]
Crossley, E., Issa, F., Scarf, A., Kassiou, M., Rendina, L. (2011). Synthesis and cellular uptake of boron-rich pyrazolopyrimidines: exploitation of the translocator protein for the efficient delivery of boron into human glioma cells. Chemical Communications, 47(44), 12179-12181. [More Information]
Moussa, I., Banister, S., Giboureau, N., Meikle, S., Kassiou, M. (2011). Synthesis and in vivo evaluation of [18F]N-(2-benzofuranylmethyl)-N'-[4-(2-fluoroethoxy)benzyl]piperazine, a novel σ1 receptor PET imaging agent. Bioorganic and Medicinal Chemistry Letters, 21(22), 6820-6823. [More Information]
Damont, A., Boisgard, R., Kuhnast, B., Lemee, F., Raggiri, G., Scarf, A., Da Pozzo, E., Selleri, S., Martini, C., Tavitian, B., Kassiou, M., et al (2011). Synthesis of 6-[(18)F]fluoro-PBR28, a novel radiotracer for imaging the TSPO 18 kDa with PET. Bioorganic and Medicinal Chemistry Letters, 21(16), 4819-4822. [More Information]
Scarf, A., Kassiou, M. (2011). The translocator protein. The Journal of Nuclear Medicine, 52(5), 677-680. [More Information]
Banister, S., Moussa, I., Beinat, C., Reynolds, A., Schiavini, P., Jorgensen, W., Kassiou, M. (2011). Trishomocubane as a Scaffold for the Development of Selective Dopamine Transporter (DAT) Ligands. Bioorganic and Medicinal Chemistry Letters, 21(1), 38-41. [More Information]
Banister, S., Clegg, J., Hanani, R., Kassiou, M. (2010). 11-{[2-(3-fluorophenyl)ethyl](methyl)-amino}pentacyclo[5.4.0.0(2,6).0(3,10).0(5,9)]-undecan-8-one. Acta Crystallographica. Section E: Structure Reports Online, 66(10), o2693-o2693. [More Information]
Naidoo (Naidoo-Variawa), S., Lehnert, W., Kassiou, M., Banati, R., Meikle, S. (2010). Attenuation correction for the large non-human primate brain imaging using microPET. Physics in Medicine and Biology, 55(8), 2351-2363. [More Information]
Morrison, D., Issa, F., Bhadbhade, M., Groebler, L., Witting, P., Kassiou, M., Rutledge, P., Rendina, L. (2010). Boronated phosphonium salts containing arylboronic acid, closo-carborane, or nido-carborane: synthesis, X-ray diffraction, in vitro cytotoxicity, and cellular uptake. Journal of Biological Inorganic Chemistry, 15(8), 1305-1318. [More Information]
Moussa, I., Banister, S., Beinat, C., Giboureau, N., Reynolds, A., Kassiou, M. (2010). Design, synthesis, and structure-affinity relationships of regioisomeric N-benzyl alkyl ether piperazine derivatives as sigma-1 receptor ligands. Journal of Medicinal Chemistry, 53(16), 6228-6239. [More Information]
Giboureau, N., Aumann, K., Beinat, C., Kassiou, M. (2010). Development of vesicular acetylcholine transporter ligands: Molecular probes for Alzheimer's disease. Current Bioactive Compounds, 6(3), 129-155. [More Information]
Abraham, M., Boisgard, R., Theze, B., Van Camp, N., Kuhnast, B., Damont, A., Kassiou, M., Dolle, F., Tavitian, B. (2010). Evaluation of the PBR/TSPO radioloigand [18F]DPA-714 in a rat model of focal cerebral ischemia. Journal of Cerebral Blood Flow and Metabolism, 30(1), 230-241. [More Information]
Banister, S., Roeda, D., Dolle, F., Kassiou, M. (2010). Fluorine-18 chemistry for PET: A concise introduction. Current Radiopharmaceuticals, 3(2), 68-80. [More Information]
Beinat, C., Banister, S., Moussa, I., Reynolds, A., McErlean, C., Kassiou, M. (2010). Insights into structure-activity relationships and CNS therapeutic applications of NR2B selective antagonists. Current Medicinal Chemistry, 17(34), 4166-4190. [More Information]
Banister, S., Moussa, I., Jordan, M., Coster, M., Kassiou, M. (2010). Oxo-bridged isomers of aza-trishomocubane sigma (o) receptor ligands: Synthesis, in vitro binding, and molecular modeling. Bioorganic and Medicinal Chemistry Letters, 20(1), 145-148. [More Information]
Gunosewoyo, H., Kassiou, M. (2010). P2X purinergic receptor ligands: Recently patented compounds. Expert Opinion on Therapeutic Patents, 20(5), 625-646. [More Information]
Giboureau, N., Mat Som, I., Boucher, A., Guilloteau, D., Kassiou, M. (2010). PET Radioligands for the Vesicular Acetylcholine Transporter (VAChT). Current Topics in Medicinal Chemistry, 10(15), 1569-1583. [More Information]
Reynolds, A., Hanani, R., Hibbs, D., Damont, A., Da Pozzo, E., Selleri, S., Dolle, F., Martini, C., Kassiou, M. (2010). Pyrazolo[1,5-a]pyrimidine acetamides: 4-Phenyl alkyl ether derivatives as potent ligands for the 18 kDa translocator protein (TSPO). Bioorganic and Medicinal Chemistry Letters, 20(19), 5799-5802. [More Information]
Luus, C., Hanani, R., Reynolds, A., Kassiou, M. (2010). The development of PET radioligands for imaging the translocator protein (18 kDa): What have we learned? Journal of Labelled Compounds and Radiopharmaceuticals, 53(7), 501-510. [More Information]
Valette, H., Xiao, Y., Schollhorn-Peyronneau, M., Damont, A., Kosikowski, A., Wei, Z., Kassiou, M., Kellar, K., Dolle, F., Bottlaender, M. (2009). 18F-ZW-104: A New Radioligand for Imaging Neuronal Nicotinic Acetylcholine Receptors-In Vitro Binding Properties and PET Studies in Baboons. The Journal of Nuclear Medicine, 50(8), 1349-1355. [More Information]
Doorduin, J., Klein, H., Dierckx, R., James, M., Kassiou, M., De Vries, E. (2009). [11C]-DPA-713 and [18F]-DPA-714 as new PET tracers for TSPO: A comparison with [11C]-(R)-PK11195 in a rat model of herpes encephalitis. Molecular Imaging and Biology, 11(6), 386-398. [More Information]
Damont, A., van Camp, N., Kuhnast, B., Hinnen, F., Boisgard, R., Chauveau, F., Boutin, H., Probst, K., Clark, J., Katsifis, A., Kassiou, M. (2009). [18F]DPA-714, [18F]PBR111 and [18F]FEDAA1106 as potent PBR pet-imaging candidates: Radiosynthesis and comparative studies. Journal of Labelled Compounds and Radiopharmaceuticals, 52(S1), S122-S122.
Truong, L., Allbutt, H., Coster, M., Kassiou, M., Henderson, J. (2009). Behavioural effects of a selective NMDA NR1A/2B receptor antagonist in rats with unilateral 6-OHDA+ parafascicular lesions. Brain Research Bulletin, 78(2-3), 91-96. [More Information]
Kassiou, M., Banati, R., Holsinger, D., Meikle, S. (2009). Challenges in molecular imaging of Parkinson's disease: A brief overview. Brain Research Bulletin, 78(2-3), 105-108. [More Information]
Chauveau, F., Van Camp, N., Dolle, F., Kuhnast, B., Hinnen, F., Damont, A., Boutin, H., James, M., Kassiou, M., Tavitian, B. (2009). Comparative evaluation of the translocator protein radioligands (11)C-DPA-713, (18)F-DPA-714, and (11)C-PK11195 in a rat model of acute neuroinflammation. The Journal of Nuclear Medicine, 50(3), 468-476. [More Information]
Warraich, S., Allbutt, H., Billing, R., Radford, J., Coster, M., Kassiou, M., Henderson, J. (2009). Evaluation of behavioural effects of a selective NMDA NR1A/2B receptor antagonist in the unilateral 6-OHDA lesion rat model. Brain Research Bulletin, 78(2-3), 85-90. [More Information]
Edington, A., McKinzie, A., Reynolds, A., Kassiou, M., Ryan, R., Vandenberg, R. (2009). Extracellular loops 2 and 4 of GLYT2 are required for N-arachidonylglycine inhibition of glycine transport. Journal of Biological Chemistry, 284(52), 36424-36430. [More Information]
Endres, C., Pomper, M., James, M., Uzuner, O., Hammoud, D., Watkins, C., Reynolds, A., Hilton, J., Dannals, R., Kassiou, M. (2009). Initial evaluation of 11C-DPA-713, a novel TSPO PET ligand, in humans. The Journal of Nuclear Medicine, 50(8), 1276-1282. [More Information]
Leaver, K., Allbutt, H., Creber, N., Kassiou, M., Henderson, J. (2009). Oral pre-treatment with epigallocatechin gallate in 6-OHDA lesioned rats produces subtle symptomatic relief but not neuroprotection. Brain Research Bulletin, 80(6), 397-402. [More Information]
Gunosewoyo, H., Coster, M., Bennett, M., Kassiou, M. (2009). Purinergic P2X(7) receptor antagonists:Chemistry and fundamentals of biological screening. Bioorganic and Medicinal Chemistry, 17(14), 4861-4865. [More Information]
Dolle, F., Luus, C., Reynolds, A., Kassiou, M. (2009). Radiolabelled molecules for imaging the translocator protein (18 kDa) using positron emission tomography. Current Medicinal Chemistry, 16(22), 2899-2923. [More Information]
Reynolds, A., Kassiou, M. (2009). Recent advances in the Mitsunobu reaction: Modifications and applications to biologically active molecules. Current Organic Chemistry, 13(16), 1610-1632. [More Information]
Scarf, A., Ittner, L., Kassiou, M. (2009). The translocator protein (18 kDa): Central nervous system disease and drug design. Journal of Medicinal Chemistry, 52(3), 581-592. [More Information]
Ioppolo, J., Kassiou, M., Rendina, L. (2009). Water-soluble phosphonium salts containing 1,12-dicarba-closo-dodecaborane(12). Tetrahedron Letters, 50(47), 6457-6461. [More Information]
Dolle, F., Damont, A., Valette, H., Hinnen, F., Kuhnast, B., Saba, W., Schollhorn-Peyronneau, M., Kozikowski, A., Bottlaender, M., Kassiou, M. (2009). ZW-102 and ZW-104, two novel fluorine-18 labelled radioligands for imaging nicotinic acetylcholine receptors with PET. Journal of Labelled Compounds and Radiopharmaceuticals, 52(S1), S364.
van Dijk, A., Johnston, C., Allbutt, H., Kassiou, M., Henderson, J. (2008). Behavioural effects of trishomocubanes in rats with unilateral 6-hydroxydopamine lesions. Behavioural Brain Research, 190(1), 14-21. [More Information]
Gunosewoyo, H., Liu, G., Bennett, M., Coster, M., Kassiou, M. (2008). Cubyl amides: Novel P2X(7) receptor antagonists. Bioorganic and Medicinal Chemistry Letters, 18(13), 3720-3723. [More Information]
Besret, L., Dolle, F., Herard, A., Guillermier, M., Demphel, S., Hinnen, F., Coulon, C., Ottaviani, M., Bottlaender, M., Hantraye, P., Kassiou, M. (2008). Dopamine D1 Receptor Imaging in the Rodent and Primate Brain Using the Isoquinoline (+)-[(11)C]A-69024 and Positron Emission Tomography. Journal of Pharmaceutical Sciences, 97(7), 2811-2819. [More Information]
James, M., Fulton, R., Vercoullie, J., Henderson, D., Garreau, L., Chalon, S., Dolle, F., Selleri, S., Guilloteau, D., Kassiou, M. (2008). DPA-714, a New Translocator Protein-Specific Ligand: Synthesis, Radiofluorination, and Pharmacologic Characterization. The Journal of Nuclear Medicine, 49(5), 814-822. [More Information]
Leaver, K., Allbutt, H., Creber, N., Kassiou, M., Henderson, J. (2008). Neuroprotective effects of a selective N-methyl-D-aspartate NR2B receptor antagonist in the 6-hydroxydopamine rat model of Parkinson's disease. Clinical and Experimental Pharmacology and Physiology, 35(11), 1388-1394. [More Information]
Henderson, J., Lanciego, J., Smith, Y., Gundlach, A., Kassiou, M. (2008). Proceedings of the 2007 International Brain Research Organisation Satellite Meeting "Movement Disorders: Focus on the Thalamus and Basal Ganglia" held in Sydney, Australia, 10-11 July, 2007. Brain Research Bulletin, 78(2-3), 53-54. [More Information]
Damont, A., Hinnen, F., Kuhnast, B., Schollhorn-Peyronneau, M., James, M., Luus, C., Tavitian, B., Kassiou, M., Dolle, F. (2008). Radiosynthesis of [(18)F]DPA-714, a selective radioligand for imaging the translocator protein (18 kDa) PET. Journal of Labelled Compounds and Radiopharmaceuticals, 51(7-8), 286-292. [More Information]
Dolle, F., Langle, S., Roger, G., Fulton, R., Lagnel, B., Henderson, D., Hinnen, F., Paine, T., Coster, M., Valette, H., Kassiou, M., et al (2008). Synthesis and In-Vivo Evaluation of [(11)C]p-PVP-MEMA as a PET Radioligand for Imaging Nicotinic Receptors. Australian Journal of Chemistry, 61(6), 438-445. [More Information]
Banister, S., Clegg, J., Coster, M., Jolliffe, K., Kassiou, M. (2007). (1R,2S,3R,6S,7R,8S)-Tricyclo[6.2.1.02,7]-undeca-4,9-diene-3,6-diol. Acta Crystallographica. Section E: Structure Reports Online, E63, o92-o93. [More Information]
Emond, P., Mavel, S., Zea-Ponce, Y., Kassiou, M., Garreau, L., Bodard, S., Drossard, M., Chalon, S., Guilloteau, D. (2007). (E)-[125I]-5-AOIBV: a SPECT radioligand for the vesicular acetylcholine transporter. Nuclear Medicine and Biology, 34(8), 967-971. [More Information]
Boutin, H., Chauveau, F., Thominiaux, C., Gregoire, M., James, M., Trebossen, R., Hantraye, P., Dolle, F., Tavitian, B., Kassiou, M. (2007). 11C-DPA-713: A novel peripheral benzodiazepine receptor PET ligand for in vivo imaging of neuroinflammation. The Journal of Nuclear Medicine, 48(4), 573-581. [More Information]
Kozikowski, A., Chellappan, S., Henderson, D., Fulton, R., Giboureau, N., Xiao, Y., Wei, Z., Guilloteau, D., Emond, P., Dolle, F., Kassiou, M., et al (2007). Acetylenic pyridines for use in PET imaging of nicotinic receptors. ChemMedChem: chemistry enabling drug discovery, 2, 54-57. [More Information]
Quinlivan, M., Chalon, S., Vergote, J., Henderson, J., Katsifis, A., Kassiou, M., Guilloteau, D. (2007). Decreased vesicular acetylcholine transporter and alpha-4beta-2 nicotinic receptor density in the rat brain following 192 IgG-saporin immunolesioning. Neuroscience Letters, 415, 97-101. [More Information]
Giboureau, N., Emond, P., Fulton, R., Henderson, D., Chalon, S., Garreau, L., Roselt, P., Eberl, S., Mavel, S., Bodard, S., Fulham, M., Kassiou, M., et al (2007). Ex vivo and in vivo evaluation of (2R,3R)-5-[18F]-fluoroethoxy- and fluoropropoxy-benzovesamicol, as PET radioligands for the vesicular acetylcholine transporter. Synapse (New York), 61(12), 962-670. [More Information]
Naidoo (Naidoo-Variawa), S., Hey Cunningham, A., Lehnert, W., Kench, P., Kassiou, M., Banati, R., Meikle, S. (2007). High-resolution imaging of the large non-human primate brain using microPET: a feasibility study. Physics in Medicine and Biology, 52(22), 6627-6638. [More Information]
Collier, T., Waterhouse, R., Kassiou, M. (2007). Imaging sigma receptors: Applications in drug development. Current Pharmaceutical Design, 13, 51-72. [More Information]
Kassiou, M. (2007). Molecular imaging in drug development (EDITORIAL). Current Pharmaceutical Design, 13(1), 1-1. [More Information]
Gunosewoyo, H., Coster, M., Kassiou, M. (2007). Molecular probes for P2X7 receptor studies. Current Medicinal Chemistry, 14(14), 1505-1523. [More Information]
Cagnin, A., Kassiou, M., Meikle, S., Banati, R. (2007). Positron emission tomography imaging of neuroinflammation. Neurotherapeutics, 4(3), 443-452. [More Information]
Liu, X., Banister, S., Christie, M., Banati, R., Meikle, S., Coster, M., Kassiou, M. (2007). Trishomocubanes: Novel sigma ligands modulate cocaine-induced behavioural effects. European Journal of Pharmacology, 555(1), 37-42. [More Information]
Truong, L., Allbutt, H., Kassiou, M., Henderson, J. (2006). Developing a preclinical model of Parkinson's disease: a study of behaviour in rats with graded 6-OHDA lesions. Behavioural Brain Research, 169(1), 1-9. [More Information]
James, M., Selleri, S., Kassiou, M. (2006). Development of ligands for the peripheral benzodiazepine receptor. Current Medicinal Chemistry, 13(17), 1991-2001. [More Information]
Thominiaux, C., Dolle, F., James, M., Bramoulle, Y., Boutin, H., Besret, L., Gregoire, M., Valette, H., Bottlaender, M., Tavitian, B., Kassiou, M., et al (2006). Improved synthesis of the peripheral benzodiazepine receptor ligand C-11 DPA-713 using C-11 methyl triflate. Applied Radiation and Isotopes, 64(5), 570-573. [More Information]
Cagnin, A., Kassiou, M., Meikle, S., Banati, R. (2006). In vivo evidence for microglial activation in neurodegenerative dementia. Acta Neurologica Scandinavica, 114(Supplement 185), 107-114. [More Information]
Thominiaux, C., de Bruin, B., Bramoulle, Y., Hinnen, F., Demphel, S., Valette, H., Bottlaender, M., Besret, L., Kassiou, M., Dolle, F. (2006). Radiosynthesis of (E)-N-(2- C-11 methoxybenzyl)-3-phenyl-acrylamidine, a novel subnanomolar NR2B subtype-selective NMDA receptor antagonist. Applied Radiation and Isotopes, 64(3), 348-354. [More Information]
Assaad, T., Mavel, S., Parsons, S., Kruse, S., Galineau, L., Allouchi, H., Kassiou, M., Chalon, S., Guilloteau, D., Emond, P. (2006). Synthesis and in vitro evaluation of N-substituted aza-trozamicol analogs as vesicular acetylcholine transporter ligands. Bioorganic and Medicinal Chemistry Letters, 16(10), 2654-2657. [More Information]
Vercouillie, J., Mavel, S., Galineau, L., Ragusa, T., Innis, R., Chalon, S., Kassiou, M., Dolle, F., Besnard, J., Guilloteau, D., et al (2006). Synthesis and in vitro evaluation of novel derivatives of diphenylsulfide as serotonin transporter ligands. Bioorganic and Medicinal Chemistry Letters, 16(5), 1297-1300. [More Information]
Issa, F., Kassiou, M., Chan, K., McLeod, M. (2006). Synthesis and radiolabelling of ipratropium and tiotropium for use as PET ligands in the study of inhaled drug deposition. Australian Journal of Chemistry, 59(1), 53-58. [More Information]
Liu, X., Banister, S., Christie, M., Banati, R., Meikle, S., Coster, M., Kassiou, M. (2006). Trishomocubanes: Novel Sigma ligands modulate cocaine-induced behavioural effects. European Journal of Pharmacology, 555(1), 37-42. [More Information]
Kassiou, M. (2005). Capabilities of PET and SPECT in pre-clinical and clinical research. Current Pharmaceutical Design, 11(25), 3201-3201. [More Information]
Liu, X., Mattner, F., Katsifis, A., Christie, M., Kassiou, M. (2005). Influence of Trishomocubanes on Sigma Receptor Binding of N-(1-Benzylpiperidin- 4-yl)-4-[123I]iodobenzamide In Vivo in the Rat Brain. Medicinal Chemistry, 1(1), 31-38. [More Information]
Kassiou, M., Meikle, S., Banati, R. (2005). Ligands for peripheral benzodiazepine binding sites in glial cells. Brain Research Reviews, 48(2), 207-210. [More Information]
Mohamed, A., Eberl, S., Fulham, M., Kassiou, M., Zaman, A., Henderson, D., Beveridge, S., Constable, C., Lo, S. (2005). Sequential 123I-iododexetimide scans in temporal lobe epilepsy: comparison with neuroimaging scans (MR imaging and F-18-FDG PET imaging). European Journal of Nuclear Medicine and Molecular Imaging, 32(2), 180-185. [More Information]
Meikle, S., Kench, P., Kassiou, M., Banati, R. (2005). Small animal SPECT and its place in the matrix of molecular imaging technologies. Physics in Medicine and Biology, 50(22), R45-R61. [More Information]
Zea-Ponce, Y., Mavel, S., Assaad, T., Kruse, S., Parsons, S., Emond, P., Chalon, S., Giboureau, N., Kassiou, M., Guilloteau, D. (2005). Synthesis and in vitro evaluation of new benzovesamicol analogues as potential imaging probes for the vesicular acetylcholine transporter. Bioorganic and Medicinal Chemistry, 13(3), 745-753. [More Information]
Kassiou, M., Dannals, R., Liu, X., Wong, D., Ravert, H., Scheffel, U. (2005). Synthesis and in vivo evaluation of a new PET radioligand for studying sigma-2 receptors. Bioorganic and Medicinal Chemistry, 13(11), 3623-3626. [More Information]
James, M., Fulton, R., Henderson, D., Eberl, S., Meikle, S., Thomson, S., Allan, R., Dolle, F., Fulham, M., Kassiou, M. (2005). Synthesis and in vivo evaluation of a novel peripheral benzodiazepine receptor PET radioligand. Bioorganic and Medicinal Chemistry. [More Information]
Henderson, D., Eberl, S., Thomson, S., Smith, A., Allan, R., Fulham, M., Loiacono, R., Kassiou, M. (2004). 3-Pyridyl Ethers As Spect Radioligands For Imaging Nicotinic Acetylcholine Receptors. Applied Radiation and Isotopes, 60(5), 669-676. [More Information]
Katsifis, A., Kassiou, M. (2004). Development Of Radioligands For In Vivo Imaging Of Gaba(A)-Benzodiazepine Receptors. Mini - Reviews in Medicinal Chemistry, 4(8), 909-921.
Dolle, F., Valette, H., Demphel, S., Coulon, C., Ottaviani, M., Bottlaender, M., Kassiou, M. (2004). Radiosynthesis And In Vivo Evaluation Of [11C]Ro-547312: A Novel Nr1/2B Subtype Selective Nmda Receptor Radioligand. Journal of Labelled Compounds and Radiopharmaceuticals, 47(13), 911-920. [More Information]
Roger, G., Dolle, F., de Bruin, B., Liu, X., Besret, L., Bramoulle, Y., Coulon, C., Ottaviani, M., Bottlaender, M., Valette, H., Kassiou, M. (2004). Radiosynthesis And Pharmacological Evaluation Of [11C]Emd-95885: A High Affinity Ligand For Nr2B-Containing Nmda Receptors. Bioorganic and Medicinal Chemistry, 12(12), 3229-3237. [More Information]
Roselt, P., Meikle, S., Kassiou, M. (2004). The Role Of Positron Emission Tomography In The Discovery And Development Of New Drugs; As Studied In Laboratory Animals. European Journal of Drug Metabolism and Pharmacokinetics, 29(1), 1-6.
Kassiou, M., Katsifis, A. (2003). PET radiochemistry in drug development and evaluation. Chemistry in Australia, 70(5), 10-12.
Katsifis, A., Mardon, K., Mattner, F., Loc'h, C., McPhee, M., Dikic, B., Kassiou, M., Ridley, D. (2003). Pharmacological evaluation of (S)-8-[123I]iodobretazenil: a radioligand for in vivo studies of central benzodiazepine receptors. Nuclear Medicine and Biology, 30(2), 191-198. [More Information]
Quinlivan, M., Mattner, F., Papazian, V., Zhou, J., Katsifis, A., Emond, P., Chalon, S., Kozikowski, A., Guilloteau, D., Kassiou, M. (2003). Synthesis and evaluation of iodine-123 labelled tricyclic tropanes as radioligands for the serotonin transporter. Nuclear Medicine and Biology, 30(7), 741-746. [More Information]
Roger, G., Lagnel, B., Besret, L., Bramoulle, Y., Coulon, C., Ottaviani, M., Kassiou, M., Bottlaender, M., Valette, H., Dolle, F. (2003). Synthesis, radiosynthesis and In Vivo evaluation of 5-[3-(4-Benzylpiperidin-1-yl) prop-1-ynyl]-1, 3-dihydrobenzoimidazol-2-[11C] one, as a potent NR 1A/2B subtype selective NMDA PET radiotracer. Bioorganic and Medicinal Chemistry, 11, 5401-5408. [More Information]
Kassiou, M., Loc'h, C., Bottlaender, M., Mardon, K., Ottaviani, M., Coulon, C., Katsifis, A., Maziere, B. (2002). (+)-[76Br]A-69024: a non-benzazepine radioligand for studies of dopamine D1 receptors using PET. Nuclear Medicine and Biology, 29(3), 295-302.
Kassiou, M., Bottlaender, M., Loc'h, C., Dolle, F., Musachio, J., Coulon, C., Ottaviani, M., Dannals, R., Maziere, B. (2002). Pharmacological evaluation of a Br-76 analog of epibatidine: a potent ligand for studying brain nicotinic acetylcholine receptors. Synapse (New York), 45(2), 95-104. [More Information]
Kassiou, M., Loc'h, C., Dolle, F., Musachio, J., Dolci, L., Crouzel, C., Dannals, R., Maziere, B. (2002). Preparation of a bromine-76 labelled analogue of epibatidine: a potent ligand for nicotinic acetylcholine receptor studies. Applied Radiation and Isotopes, 57(5), 713-717.
Kassiou, M., Eberl, S., Meikle, S., Birrell, A., Constable, C., Fulham, M., Wong, D., Musachio, J. (2001). In vivo imaging of nicotinic receptor upregulation following chronic (-)-nicotine treatment in baboon using SPECT. Nuclear Medicine and Biology, 28, 165-175.
Kassiou, M., Mardon, K., Mattner,, F., Katsifis, A., Dikic, B. (2001). Pharmacological evaluation of (+)-2-[123I]A-69024: A radioligand for in vivo studies of dopamine D1 receptors. Life Sciences, 69, 669-675.
Liu, X., Christie, M., Kassiou, M., Nuwayhid, S., Werling, L. (2001). Trishomocubanes: Novel sigma-ligands modulate amphetamine-stimulated [3H]dopamine release. European Journal of Pharmacology, 422, 39-45.
Liu, X., Kassiou, M., Christie, M., Hambley, T. (2001). Trishomocubanes: requirements for sigma receptor binding and subtype selectivity. Australian Journal of Chemistry, 54, 31-36.
Show 182 more
Conferences
Fulham, M., Kassiou, M., Greguric, I., Thomson, S., Eberl, S., Tiam, P., Mattner, F., Henderson, D., Fulton, R., Katsifis, A., et al (2012). Synthesis and in vivo evaluation of arylalkyl 4-benzyl piperidines as radioligands for sigma receptors. 16th International Symposium on Radiopharmaceutical Chemistry, United Kingdom: Wiley.
Fulton, R., Meikle, S., Kyme, A., Zhou, W., Popovic, K., Kassiou, M., Akhtar, M. (2010). Motion-corrected microPET brain imaging of conscious rats. 2009 World Molecular Imaging Conference, USB drive/online: Online.
Banister, S., Coster, M., Kassiou, M. (2009). A versatile polycyclic scaffold for the discovery of selective sigma (sigma) receptor ligands. 7th AFMC International Medicinal Chemistry Symposium, Cairns.
Kassiou, M. (2009). Discovery of new therapeutic immunomodulator drugs as a pathway for treating brain disease. Plant Nutraceuticals and Bioactive Molecules: A Growth Opportunity for the Pharmaceutical Industry in Australia and India, N/A: N/A.
Kassiou, M. (2009). Imaging immune response in the CNS - Applications for therapeutic development. 7th AFMC International Medicinal Chemistry Symposium, Cairns.
Moussa, I., Coster, M., Kassiou, M. (2009). Synthesis and pharmacological evaluation of novel sigma receptor ligands. 7th AFMC International Medicinal Chemistry Symposium, Cairns.
Fulton, R., Kyme, A., Zhou, V., Leaver, K., Kassiou, M., Lehnert, W., Meikle, S. (2008). Progress towards microPET imaging of small, awake laboratory animals. 2008 World Molecular Imaging Congress, Europe: World Molecular Imaging Congress.
Doorduin, J., Klein, H., James, M., Kassiou, M., Dierckx, R., Vries, E. (2007). (18F)DPA-714 as a novel PET tracer for PBR: A comparison with (11C)PK11195 in a rat model of HSV encephalitis. 17th International Symposium on Radiopharmaceutical Sciences. John Wiley & Sons.
James, M., Fulton, R., Vercouille, J., Henderson, D., Garreau, L., Eberl, S., Chalon, S., Selleri, S., Dolle, F., Guilloteau, D., Kassiou, M. (2007). DPA-714 A new translocator protein (18kDa) ligand: Synthesis, radiofluorination and pharmacological characterisation. 17th International Symposium on Radiopharmaceutical Sciences. John Wiley & Sons.
Mavel, S., Zea-Ponce, Y., Garreau, L., Chalon, S., Kassiou, M., Guilloteau, D., Emond, P. (2007). E-((R,R) and (S,S))-5-(125I)-AOIBV: Potential SPECT tracers in vivo studies of the vesicular AcetylCholine Transporter (VACht). 17th International Symposium on Radiopharmaceutical Sciences. John Wiley & Sons.
Kassiou, M., Chellappan, S., Henderson, D., Fulton, R., Giboureau, N., Xiao, Y., Wei, Z., Guilloteau, D., Emond, P., Dolle, F., et al (2007). Radiosynthesis and preliminary evaluation of ZW-90 and ZW-110, two novel acetylenic pyridines for imaging nicotonic receptors. 17th International Symposium on Radiopharmaceutical Sciences. John Wiley & Sons.
Giboureau, N., Chalon, S., Garreau, L., Kassiou, M., Emond, P., Guilloteau, D. (2007). Rat distribution of (18F)-Fuoropropoxy- and (18F)-Fluoroethoxybenzovesamicol, as PET radioligands for the vesicular acetylcholine transporter (VACht). 17th International Symposium on Radiopharmaceutical Sciences. John Wiley & Sons.
Creelman, A., Thominiaux, C., Chauveau, F., Fulton, R., Kuhnast, B., Henderson, D., Boutin, H., Selleri, S., McGregor, I., Hantraye, P., Kassiou, M., et al (2007). Synthesis and evaluation of the translocator protein (18kDa) (TSPO) ligand (11C)DPA0715 in rat and non-human primate. 17th International Symposium on Radiopharmaceutical Sciences. John Wiley & Sons.
Langley, S., Roger, G., Fulton, R., Lagnel, B., Henderson, D., Hinnen, F., Bottlaender, M., Dolle, F., Kassiou, M. (2007). Synthesis and in vivo evaluation of (11c)P-PVP-MEMA as a PET radioligand for Imaging nicotonic receptors. 17th International Symposium on Radiopharmaceutical Sciences. John Wiley & Sons.
Kassiou, M., Bruin, B., Demphel, S., Besret, L., Hinnen, F., Dolle, F., Bramoulle, Y., Thominiaux, C., Bottlaender, M. (2005). Radiosynthesis of (E)-N-(2-[11C]methoxybenzyl)-3-phenyl-acrylamidine, a novel subnanomolar NR2B subtype-selective NMDA receptor ligand. 16th International Symposium on Radiopharmaceutical Chemistry, United Kingdom: Wiley.
Fulham, M., Kassiou, M., Dolle, F., Thomson, S., Henderson, D., James, M., Eberl, S., Fulton, R., Allan, R. (2005). Synthesis and In Vivo Evaluation of a Novel Peripheral Benzodiazepine Receptor PET Radioligand. 16th International Symposium on Radiopharmaceutical Chemistry, United Kingdom: Wiley.
Feng, D., Kassiou, M., Fulham, M., Wong, K., Elberl, S. (2003). Quantification of 5-[123I]iodo-A-85380 in nonhuman primates using spect: parameter identifiability and stabilitty. Modelling and Control in Biomedical Systems 2003 (Including Biological Systems), UK: Pergamon.
Show 14 more
Patents
Kassiou, M., James, M., Luus, C. (2013). Translocator Protein Ligands (USA). Patent No. 8492379.
Kassiou, M., James, M. (2010). 2-Arylpyrazolo[L,5-a]Pyrimidin-3-yl Acetamide Deriv As Ligands For Translocator Protein. Patent No. 2008/10473. South Africa.
Kassiou, M., James, M., Luus, C. (2009). Patent No. WO2009079683 (A1).
Back to Top
To update your profile click here. For support on your academic profile contact Research Support.
© 2002-17 The University of Sydney. Last updated: 11 April 2013
ABN: 15 211 513 464. CRICOS number: 00026A. Phone: +61 2 9351 2222.
Authorised by: Dean, Faculty of Science.
Contact the University | Disclaimer | Privacy | Accessibility
Sitemap
Current students
Future students
Research
Alumni
For staff
Online Store
About the Faculty
News
Contact us